Stockscreener 앱 받기
4.58
4.58%
-0.22
시간 외 거래:
4.99
0.41
+8.95%
전일 마감가:
$4.80
열려 있는:
$4.952
하루 거래량:
1.11M
Relative Volume:
1.85
시가총액:
$351.20M
수익:
$1,000.00K
순이익/손실:
$-48.81M
주가수익비율:
-5.9196
EPS:
-0.7737
순현금흐름:
$-39.95M
1주 성능:
-23.03%
1개월 성능:
-29.97%
6개월 성능:
+47.74%
1년 성능:
+332.08%
1일 변동 폭
$4.37
$5.17
1주일 범위
$4.37
$5.995
52주 변동 폭
$0.712
$8.33
셰턱랩스 Stock (STTK) Company Profile
명칭
Shattuck Labs Inc
전화
512-900-4690
주소
500 W. 5TH STREET, AUSTIN
Compare STTK vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
STTK
Shattuck Labs Inc
|
4.58 | 368.07M | 1,000.00K | -48.81M | -39.95M | -0.7737 |
VRTX
Vertex Pharmaceuticals Inc
|
446.83 | 112.12B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
635.45 | 65.92B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
891.32 | 52.38B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.05 | 40.54B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.23 | 33.10B | 742.00K | -1.37B | -1.07B | -7.0731 |
셰턱랩스 Stock (STTK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-27 | 개시 | Cantor Fitzgerald | Overweight |
| 2026-03-06 | 재개 | Needham | Buy |
| 2026-01-28 | 개시 | Piper Sandler | Overweight |
| 2025-12-01 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-09-08 | 개시 | Wedbush | Outperform |
| 2025-03-17 | 개시 | Leerink Partners | Outperform |
| 2024-10-02 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-10-02 | 다운그레이드 | Needham | Buy → Hold |
| 2024-10-01 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-06-17 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2022-08-31 | 개시 | BTIG Research | Buy |
| 2022-06-01 | 개시 | Citigroup | Buy |
| 2022-05-02 | 개시 | H.C. Wainwright | Buy |
| 2021-04-14 | 개시 | Berenberg | Buy |
| 2021-01-11 | 개시 | Evercore ISI | Outperform |
| 2020-11-03 | 개시 | Citigroup | Buy |
| 2020-11-03 | 개시 | Cowen | Outperform |
| 2020-11-03 | 개시 | Needham | Buy |
모두보기
셰턱랩스 주식(STTK)의 최신 뉴스
Shattuck Labs to present Phase 1 SL-325 data on June 8 - scanx.trade
Shattuck Labs to present phase 1 data for SL-325 on Monday - Investing.com UK
Shattuck Labs to present phase 1 data for SL-325 on Monday By Investing.com - Investing.com South Africa
STTK Upgraded by Citigroup -- Rating Raised to Buy - GuruFocus
Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8 - The Manila Times
Shattuck Labs to Present Phase 1 Clinical Data for SL-325 and Pipeline Update on June 8, 2026 - Quiver Quantitative
Shattuck Labs' High-Stakes Bet on a New Era for Autoimmune Treatment - BriefGlance
Shattuck Labs (STTK) Receives Upgrade and Catalyst Watch from Ci - GuruFocus
Citigroup Upgrades Shattuck Labs to Buy From Neutral, Price Target is $7 - marketscreener.com
Citigroup Upgrades Shattuck Labs to Buy From Neutral, Price Target Is $7 - Moomoo
Shattuck Labs (STTK) Receives Upgrade and Catalyst Watch from Citi - GuruFocus
Shattuck Labs, Inc. Amends and Restates 2020 Equity Incentive Plan – SEC 8-K Filing Details - Minichart
Shattuck Labs (STTK) director gets 81,000 stock options at $5.95 - Stock Titan
Shattuck Labs (STTK) director Neil Gibson receives 81,000 stock options at $5.95 - Stock Titan
Shattuck Labs (STTK) investors approve equity plan boost and annual say-on-pay - Stock Titan
Shattuck Labs (STTK) Slips 1.49% as Stock Nears Critical Support at $5.67Value Area Low - The Legal Advocate
STTK Q1 2026 Earnings: Narrower Loss Surprises as Biotech Advances PipelineManagement Guidance Update - The Legal Advocate
Director Clay B. Siegall doubles Shattuck Labs (STTK) holdings with warrant exercise - Stock Titan
Shattuck Labs (STTK) Holds Near Support as Biotech Sentiment ShiftsBearish Sentiment - The Legal Advocate
Shattuck Labs (STTK) Holds Steady at $6.1, Testing Familiar Support LevelsOBV Breakout - Newser
STTK Q1 2026 Earnings: Shattuck Labs Reports Narrower Loss, Beats EPS EstimatesEarnings Yield Analysis - The Legal Advocate
STTK Q1 2026 Earnings: Narrower Loss Surprises, No Revenue as Pipeline Progress ContinuesROIC Trend Report - newsline.com
STTK Q1 2026 Earnings: Narrower-than-expected loss highlights cost discipline amid pre-revenue stageAnnual Report - Newser
Number of shareholders of Shattuck Labs, Inc. – NASDAQ:STTK - TradingView
STTK Insider Buying: CTO Shukla Acquires 5,122 Shares on May 22, 2026 - Meyka
Shattuck Labs (NASDAQ: STTK) CTO exercises 5,122 warrants and increases share holdings - Stock Titan
Shattuck Labs: Priced As If Risk Was Not A Part Of The Equation (NASDAQ:STTK) - Seeking Alpha
Here's Why We're Not Too Worried About Shattuck Labs' (NASDAQ:STTK) Cash Burn Situation - Sahm
Officer at Shattuck Labs (NASDAQ: STTK) exercises warrants for 12,805 shares - Stock Titan
Shattuck Labs (STTK) Stock Analysis: -6.15% Loss — Key Levels 2026-05-15Social Trading Insights - newser.com
Shattuck Labs (STTK) Declines -6.15% Amid Market Weakness 2026-05-15Trading Community - newser.com
Shattuck Labs (STTK) Delivers Q1 2026 Beat — EPS $-0.13 vs $-0.14 ExpectedSpecial Dividend - newser.com
T. Rowe Price holds 9.87M shares of Shattuck Labs (NASDAQ: STTK) amendment - Stock Titan
Shattuck Labs CMO Pandite sells $198,300 in stock By Investing.com - Investing.com Nigeria
Insider Sell: Arundathy Pandite Sells 30,000 Shares of Shattuck Labs Inc (STTK) - GuruFocus
Shattuck Labs CTO Abhinav Shukla sells $14,244 in shares - Investing.com UK
Shattuck Labs CMO Pandite sells $198,300 in stock - Investing.com
Shattuck Labs CTO Abhinav Shukla sells $14,244 in shares By Investing.com - Investing.com Australia
[Form 4] Shattuck Labs, Inc. Insider Trading Activity - Stock Titan
Shattuck Labs (STTK) CMO sells 30K shares under 10b5-1 plan - Stock Titan
Shattuck Labs stock (US8124231002): Down 5.29% in May 2026 amid biotech volatility - AD HOC NEWS
Shattuck Labs (STTK) CEO exercises warrants to acquire 25,610 common shares - Stock Titan
Shattuck Labs (NASDAQ: STTK) executive reports 968-share tax withholding - Stock Titan
[144] Shattuck Labs, Inc. SEC Filing - Stock Titan
We're Not Very Worried About Shattuck Labs' (NASDAQ:STTK) Cash Burn Rate - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Shattuck Labs (STTK), Novavax (NVAX) and Airsculpt Technologies (AIRS) - The Globe and Mail
STTK Maintained by Wedbush -- Price Target Raised to $11.00 - GuruFocus
Shattuck Labs Price Target Raised to $11.00/Share From $8.00 by Wedbush - Moomoo
셰턱랩스 (STTK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
셰턱랩스 주식 (STTK) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Shukla Abhinav A. | Chief Technical Officer |
May 12 '26 |
Sale |
7.01 |
2,032 |
14,244 |
81,258 |
| Pandite Arundathy N. | Chief Medical Officer |
May 12 '26 |
Sale |
6.61 |
30,000 |
198,300 |
166,219 |
1.13%
3.22%
자본화:
|
볼륨(24시간):